EGFR Non-Small Cell Lung Cancer Market Report 2026

EGFR Non-Small Cell Lung Cancer Market Overview

• EGFR Non-Small Cell Lung Cancer market size has reached to $9.34 billion in 2025 • Expected to grow to $13.74 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: Rising Adoption Of Personalized Medicine Driving The Growth Of The Market Due To Targeted Therapy And Improved Patient Outcomes • Market Trend: Advancements In EGFR-Targeted Therapies Using Antibody-Drug Conjugates For NSCLC • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under EGFR Non-Small Cell Lung Cancer Market?

Epidermal growth factor receptor (EGFR) non-small cell lung cancer refers to a subtype of non-small cell lung cancer characterized by mutations or alterations in the epidermal growth factor receptor gene, which plays a critical role in cell growth and division. These genetic changes lead to uncontrolled tumor growth and cancer progression in lung tissue. Epidermal growth factor receptor non-small cell lung cancer is commonly treated using targeted therapies designed to inhibit abnormal receptor signaling and slow disease advancement. The main drug types of epidermal growth factor receptor (EGFR) non-small cell lung cancer include tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and late phase drugs. Tyrosine kinase inhibitors (TKIs) refer to targeted therapies that block the enzymatic activity of the EGFR protein, preventing cancer cell proliferation and tumor growth. These drugs are used for mutation types including exon 19 deletions, exon 21 L858R substitution mutations, exon 20 insertion mutations, and other mutation types. They are available in treatment types such as monotherapy and combination therapy, and administered via oral or intravenous routes. They are used by end users including hospitals, specialty oncology centers, cancer research institutes, academic institutes, and other end users.

What Is The EGFR Non-Small Cell Lung Cancer Market Growth Forecast?

The egfr non-small cell lung cancer market size is expected to see strong growth in the next few years. It will grow to $13.74 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing pipeline of next-generation egfr inhibitors, rising adoption of precision oncology approaches, expansion of biomarker-driven treatment models, growing integration of real-world evidence in oncology care, increasing focus on patient-centric cancer management. Major trends in the forecast period include increasing adoption of targeted egfr therapies, rising use of companion diagnostic testing, growing focus on personalized treatment pathways, expansion of combination therapy approaches, enhanced integration of multidisciplinary cancer care.

Global EGFR Non-Small Cell Lung Cancer Market Segmentation

1) By Drug Type: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies; Late Phase 2) By Mutation Type: Exon 19 Deletions; Exon 21 L858R Substitution Mutations; Exon 20 Insertion Mutations; Other Mutation Types 3) By Treatment Type: Monotherapy; Combination Therapy 4) By Route of Administration: Oral; Intravenous 5) By End User: Hospitals; Specialty Oncology Centers; Cancer Research Institutes; Academic Institutes; Other End Users Subsegments: 1) By Tyrosine Kinase Inhibitors: First Generation Tyrosine Kinase Inhibitors; Second Generation Tyrosine Kinase Inhibitors; Third Generation Tyrosine Kinase Inhibitors 2) By Monoclonal Antibodies: Anti Epidermal Growth Factor Receptor Monoclonal Antibodies; Dual Target Monoclonal Antibodies; Antibody Drug Conjugates 3) By Late Phase: Patritumab Deruxtecan; Other Late Phase Pipeline Therapies

What Is The Driver Of The EGFR Non-Small Cell Lung Cancer Market?

The increasing focus on personalized medicine approaches is expected to propel the growth of the epidermal growth factor receptor (EGFR) non-small cell lung cancer market going forward. Personalized medicine is a medical approach that tailors prevention, diagnosis, and treatment strategies to an individual’s genetic, environmental, and lifestyle factors. Personalized medicine approaches are rising due to the growing accessibility of genetic and molecular profiling, which enables precise identification of disease-specific targets and allows treatments to be tailored for improved patient outcomes. Personalized medicine approaches support EGFR non-small cell lung cancer by detecting specific EGFR mutations in patients, allowing doctors to prescribe targeted therapies that maximize effectiveness while minimizing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA authorized 16 new personalized therapies for patients with rare diseases in 2023, a significant increase from the six approvals recorded in 2022. Therefore, the increasing focus on personalized medicine approaches is driving the growth of the epidermal growth factor receptor (EGFR) non-small cell lung cancer market.

Key Players In The Global EGFR Non-Small Cell Lung Cancer Market

Major companies operating in the egfr non-small cell lung cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., AstraZeneca Plc, Bayer AG, Eli Lilly and Company, Takeda Pharmaceuticals Company Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd., Betta Pharmaceuticals Co. Ltd., ShanghAI Allist Pharmaceuticals Co. Ltd., Oric Pharmaceuticals Inc., Black Diamond Therapeutics Inc., G1 Therapeutics Inc., Dizal Pharmaceutical, ArriVent BioPharma Inc., and Cullinan Therapeutics Inc.

Global EGFR Non-Small Cell Lung Cancer Market Trends and Insights

Major companies operating in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market are focusing on developing innovative products, such as antibody drug conjugates, to improve treatment efficacy while reducing systemic side effects compared to conventional chemotherapy. An antibody-drug conjugate (ADC) is a therapy that links a cancer-targeting antibody to a powerful drug, allowing the medication to be delivered directly to tumor cells while sparing normal cells. For instance, in June 2025, AstraZeneca Plc, a UK-based biopharmaceutical company, announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received approval in the U.S. for treating adult patients with locally advanced or metastatic EGFR‑mutated non-small cell lung cancer (NSCLC) who have previously undergone EGFR-targeted therapy and platinum-based chemotherapy. This indication was granted accelerated approval based on the observed objective response rate (ORR) and duration of response (DoR), with continued approval dependent on confirmation of clinical benefit in a subsequent trial. The U.S. FDA granted the approval following Priority Review and Breakthrough Therapy Designation. The decision was supported by a subgroup analysis from the TROPION-Lung05 Phase II trial and additional evidence from the TROPION-Lung01 Phase III trial.

What Are Latest Mergers And Acquisitions In The EGFR Non-Small Cell Lung Cancer Market?

In October 2023, Daiichi Sankyo, a Japan-based company specializing in EGFR non-small cell lung cancer (NSCLC) treatment, collaborated with Merck Co. Inc. to create and bring to market three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates. As a result of the collaboration, the companies will jointly develop and potentially commercialize atritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd) worldwide, with Daiichi Sankyo retaining exclusive rights in Japan and sole responsibility for manufacturing and supply. Notably, patritumab deruxtecan has received breakthrough therapy designation from the U.S. FDA for treating patients with EGFR mutated locally advanced or metastatic NSCLC whose disease progressed after third-generation tyrosine kinase inhibitors and platinum-based therapies. Merck Co. Inc. is a US-based pharmaceutical company.

Regional Insights

North America was the largest region in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the EGFR Non-Small Cell Lung Cancer Market?

The epidermal growth factor receptor (EGFR) non-small cell lung cancer market consists of revenues earned by entities by providing services such as pathological and diagnostic evaluation, personalized treatment planning, immunotherapy support services, radiation oncology services, patient consultation and clinical management, adverse event management, and supportive and palliative care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The epidermal growth factor receptor (EGFR) non-small cell lung cancer market also includes sales of companion diagnostic kits, biomarker testing assays, supportive care drugs, and combination chemotherapy regimens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the EGFR Non-Small Cell Lung Cancer Market Report 2026?

The egfr non-small cell lung cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the egfr non-small cell lung cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.